Holen Sie sich die Stockscreener-App
38.43
6.75%
2.43
Handel nachbörslich:
37.82
-0.61
-1.59%
Schlusskurs vom Vortag:
$36.00
Offen:
$38.05
24-Stunden-Volumen:
124.06K
Relative Volume:
1.13
Marktkapitalisierung:
$424.87M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+35.22%
1M Leistung:
+70.50%
6M Leistung:
+195.84%
1J Leistung:
+0.00%
1-Tages-Spanne:
$37.81
$38.74
1-Wochen-Bereich:
$28.19
$38.74
52-Wochen-Spanne:
$11.17
$38.74
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Firmenname
Palvella Therapeutics Inc
Sektor
Branche
Telefon
(484) 253-1461
Adresse
125 STRAFFORD AVE, WAYNE
Vergleichen Sie PVLA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
38.43 | 398.00M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-04-09 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-26 | Eingeleitet | Stifel | Buy |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-02-05 | Eingeleitet | TD Cowen | Buy |
| 2024-12-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-03-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-03-19 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-19 | Eingeleitet | Jefferies | Buy |
| 2018-01-16 | Bestätigt | H.C. Wainwright | Buy |
| 2017-05-30 | Eingeleitet | Rodman & Renshaw | Buy |
| 2016-08-05 | Fortgesetzt | ROTH Capital | Buy |
| 2015-08-12 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-07-27 | Eingeleitet | Oppenheimer | Outperform |
| 2015-07-22 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Palvella Therapeutics Inc Aktie (PVLA) Neueste Nachrichten
Palvella Therapeutics Inc. Stock Analysis and ForecastOutstanding capital appreciation - Autocar Professional
Palvella Therapeutics Inc (PVLA) Stock: A Year of Highs and Lows in the Market - investchronicle.com
A Great Week for Institutional Investors Who Own 27% of Palvella Therapeutics, Inc. (NASDAQ:PVLA) - 富途牛牛
Is Palvella Therapeutics Inc. a good long term investmentHigh-yield portfolio picks - Autocar Professional
What analysts say about Palvella Therapeutics Inc. stockHigh-yield portfolio picks - jammulinksnews.com
Truist Securities initiates Palvella Therapeutics stock with Buy rating By Investing.com - Investing.com Canada
What drives Palvella Therapeutics Inc. stock priceSuperior stock growth - jammulinksnews.com
What makes Palvella Therapeutics Inc. stock price move sharplyLow Risk Consistent Winners - Newser
Why Palvella Therapeutics Inc. stock attracts strong analyst attentionLow Risk Entry Points - Newser
How Palvella Therapeutics Inc. stock performs during market volatilityTop Performing Low Risk Stocks - Newser
Palvella Therapeutics Secures New Patent for QTORIN™ Rapamycin - MSN
Palvella Therapeutics Completes Enrollment for Pivotal Phase 3 Trial of QTORIN Rapamycin - Insider Monkey
Is Palvella Therapeutics (NASDAQ:PVLA) A Risky Investment? - simplywall.st
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of “Buy” by Analysts - Defense World
2,516 Shares in Palvella Therapeutics, Inc. (NASDAQ:PVLA) Purchased by Spire Wealth Management - Defense World
Palvella Therapeutics Joins Russell 3000 and Russell 2000 Indexes - MSN
Palvella Therapeutics, Inc.(NasdaqCM: PVLA) added to Russell 3000 Value Index - MarketScreener
Palvella Therapeutics, Inc. Added to Russell 3000® and Russell 2000® Indexes as of June 30, 2025 - Nasdaq
Palvella Therapeutics Announces Completion of Phase 3 SELVA Trial for QTORIN Rapamycin - MyChesCo
Breakthrough Therapy: Phase 3 Trial Exceeds Target by 25% for First-Ever Microcystic LM Treatment - Stock Titan
Palvella Therapeutics Receives US Patent for Qtorin Topical Gel Candidate - MarketScreener
Palvella Therapeutics Granted Sixth U.S. Patent Covering - GlobeNewswire
Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1-20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors - The Manila Times
Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of - Bluefield Daily Telegraph
Palvella's Game-Changing QTORIN Patent Locks in 15+ Years of Market Protection for Rare Disease Treatment - Stock Titan
Palvella Therapeutics Secures FDA Grant Funding for Phase 3 Trial of QTORIN Rapamycin - MSN
Cantor Fitzgerald Weighs in on PVLA FY2026 Earnings - Defense World
Palvella Therapeutics Holds Annual Stockholders Meeting - TipRanks
Palvella Therapeutics (NASDAQ:PVLA) Receives $46.29 Consensus Price Target from Analysts - Defense World
Palvella Therapeutics receives FDA grant for rare disease trial By Investing.com - Investing.com South Africa
Palvella Therapeutics Says Top-Line Data From SELVA Expected In Q1 2026 - marketscreener.com
Palvella Therapeutics receives FDA grant for rare disease trial - Investing.com
Palvella Therapeutics Receives Initial Proceeds from FDA - GlobeNewswire
Citadel Advisors LLC Makes New Investment in Palvella Therapeutics (NASDAQ:PVLA) - Defense World
Palvella Therapeutics Names Ashley Kline Chief Commercial Officer - MSN
Palvella Therapeutics Advances in Rare Skin Disease Therapies - TipRanks
A great week for institutional investors who own 26% of Palvella Therapeutics, Inc. (NASDAQ:PVLA) - simplywall.st
Finanzdaten der Palvella Therapeutics Inc-Aktie (PVLA)
Es liegen keine Finanzdaten für Palvella Therapeutics Inc (PVLA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
4.91%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):